Published in J Clin Oncol on May 05, 2008
A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res (2009) 1.18
Drug development in the targeted therapy era. J Clin Oncol (2008) 0.75
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Drug penetration in solid tumours. Nat Rev Cancer (2006) 9.80
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst (2007) 7.10
Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst (2010) 3.94
Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer (2005) 3.58
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol (2011) 3.46
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res (2007) 3.41
Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA (2003) 3.36
Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol (2013) 2.92
Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer (2008) 2.89
Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. J Clin Oncol (2009) 2.66
Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst (2011) 2.66
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst (2013) 2.54
Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol (2005) 2.42
The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res (2005) 2.33
Placebo effects in oncology. J Natl Cancer Inst (2003) 2.23
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst (2007) 2.14
When are "positive" clinical trials in oncology truly positive? J Natl Cancer Inst (2010) 2.09
The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol (2012) 1.98
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer (2014) 1.93
Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer. J Gen Intern Med (2006) 1.88
Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol (2010) 1.86
Screening trials are even more difficult than we thought they were. J Natl Cancer Inst (2002) 1.76
MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome. Biomaterials (2011) 1.71
Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol (2007) 1.69
Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol (2003) 1.63
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol (2011) 1.62
The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res (2006) 1.58
Trials in palliative treatment--have the goal posts been moved? Lancet Oncol (2008) 1.57
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer (2011) 1.55
Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res (2005) 1.48
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer (2009) 1.45
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol (2011) 1.43
Company stock prices before and after public announcements related to oncology drugs. J Natl Cancer Inst (2011) 1.42
ASCO core values. J Clin Oncol (2006) 1.40
HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst (2012) 1.37
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol (2010) 1.31
Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. J Clin Oncol (2013) 1.28
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Abiraterone in Metastatic Prostate Cancer. N Engl J Med (2017) 1.27
Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol (2005) 1.26
Assessing cognitive function in cancer patients. Support Care Cancer (2006) 1.25
Evolution of the randomized controlled trial in oncology over three decades. J Clin Oncol (2008) 1.25
Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol (2010) 1.22
Sorafenib for metastatic renal cancer: the Princess Margaret experience. Am J Clin Oncol (2008) 1.22
Sunitinib in solid tumors. Expert Opin Investig Drugs (2009) 1.20
Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study. Cancer (2014) 1.19
Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol (2010) 1.18
Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer? Eur J Cancer (2011) 1.16
Evaluation of treatment benefit: randomized controlled trials and population-based observational research. J Clin Oncol (2013) 1.15
Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat Clin Pract Oncol (2008) 1.14
The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer (2010) 1.14
A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer (2007) 1.13
Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol (2011) 1.11
Compendium of unpublished phase III trials in oncology: characteristics and impact on clinical practice. J Clin Oncol (2011) 1.10
Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: repopulation as a cause of treatment failure? J Clin Oncol (2006) 1.08
Multidimensional challenges in clinical drug development, regulatory approval, and marketing. J Clin Oncol (2013) 1.07
The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol (2013) 1.07
Ethics in oncology: consulting for the investment industry. J Clin Oncol (2007) 1.06
Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings. J Clin Oncol (2007) 1.05
Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. Am J Clin Oncol (2013) 1.05
Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Metastasis Rev (2013) 1.03
The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol (2002) 1.01
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J (2013) 1.00
Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. Int J Radiat Oncol Biol Phys (2004) 0.98
Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psychooncology (2006) 0.98
Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer? Cancer Cell (2012) 0.96
Quality of abstracts describing randomized trials in the proceedings of American Society of Clinical Oncology meetings: guidelines for improved reporting. J Clin Oncol (2004) 0.96
The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. BMC Cancer (2009) 0.95
Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Clin Cancer Res (2009) 0.94
Targeting DNA repair in breast cancer: a clinical and translational update. Cancer Treat Rev (2010) 0.93
The tumor microenvironment and strategies to improve drug distribution. Front Oncol (2013) 0.93
A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. Cancer Chemother Pharmacol (2006) 0.93
Reduction of intracellular pH as a strategy to enhance the pH-dependent cytotoxic effects of melphalan for human breast cancer cells. Clin Cancer Res (2005) 0.91
Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy. Int J Cancer (2013) 0.91
Enhanced drug delivery in rabbit VX2 tumours using thermosensitive liposomes and MRI-controlled focused ultrasound hyperthermia. Int J Hyperthermia (2012) 0.91
Use of molecular biomarkers to quantify the spatial distribution of effects of anticancer drugs in solid tumors. Mol Cancer Ther (2013) 0.89
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs (2010) 0.89
Do we have to change the way targeted drugs are developed? J Clin Oncol (2010) 0.88
The evolving landscape of protein kinases in breast cancer: clinical implications. Cancer Treat Rev (2012) 0.88
Broadening horizons in medical management of prostate cancer. Acta Oncol (2011) 0.88
Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study. Breast Cancer Res Treat (2005) 0.88
"PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metaststic prostate cancer. J Urol (2002) 0.88
The effects of chemotherapy on cognitive function in a mouse model: a prospective study. Clin Cancer Res (2012) 0.88
The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res (2009) 0.87
Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil. Cancer Res (2003) 0.86
Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: a case for more innovation. JAMA (2004) 0.86
Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol (2007) 0.86
Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer (2002) 0.86
Tumor physiology and resistance to chemotherapy: repopulation and drug penetration. Cancer Treat Res (2002) 0.85
The transition from phase II to phase III studies. J Clin Oncol (2009) 0.84
Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Clin Cancer Res (2013) 0.84